Jazz Pharmaceuticals (JAZZ) PT Raised to $275 at TD Cowen

May 6, 2026 8:18 AM

TD Cowen analyst Joseph Thome, Ph.D raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $275.00 (from $220.00) while maintaining a Buy rating.

No results found